Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Cottu, Paul; D’Hondt, Véronique; Dureau, Sylvain; Lerebours, F.; Desmoulins, Isabelle; Heudel, Pierre‐Etienne; Duhoux, FP; Lévy, Christelle; Mouret‐Reynier, Marie‐Ange; Dalenc, Florence; Frenel, Jean‐Sébastien; Jouannaud, Christelle; Venat‐Bouvet, Laurence; Nguyen, Suzanne; Ferrero, J-M.; Luc Canon, Jean; Grenier, John‐Paul; Callens, Céline; Gentien, David; Lemonnier, Jérôme; Vincent‐Salomon, Anne; Delaloge, Suzette

doi:10.1093/annonc/mdy448

Public

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Published in Annals of Oncology • Oct 10, 2018

Authors:

Paul Cottu

Véronique D’Hondt

Sylvain Dureau

Abstract

Background: Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozole-palbociclib (LETPAL) combination as neoadjuvant treatment i...

Subject

Medicine

Palbociclib

Letrozole

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!